SFDA Tightens TCM Injection Regulations
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration recently released the basic technology requirements for traditional Chinese medicine and natural injection to tackle problems in TCM injection such as complicated chemical ingredients, poor preparation technology, shoddy standards, and undeterminate clinical effects. The new regulation requires TCM and natural product injection to identify their ingredients, with single-ingredient TCM injections attaining a purity level of 90 percent. It also seeks to regulate injections with altered route of administration or dosage and better guidelines for generic drugs. Besides imposing more control on non-clinical study and clinical trials, SFDA proposes a surveillance system on adverse drug reactions. Industry observers believe that the stricter regulations will raise TCM production safety and efficacy. (Click here for more
You may also be interested in...
China Recalls Contaminated TCM Injection
SHANGHAI - China has ordered a recall of two batches of acanthopanax-based injections, also know as Siberian ginseng, after reports of serious adverse reactions that caused the death of three patients in Yunan Province, China's Ministry of Health announced Oct. 11
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.